Ductal Carcinoma In Situ
Also known as: Ductal Carcinoma In-situ / Intraductal carcinoma in situ of breast / Non-infiltrating intraductal carcinoma (morphologic abnormality) / Intraductal carcinoma in situ of breast (disorder) / Carcinoma, Intraductal, Noninfiltrating / Carcinoma in situ of breast ductal / Intraductal proliferative breast lesion
Drug | Drug Name | Drug Description |
---|---|---|
DB00675 | Tamoxifen | A selective estrogen receptor modulator used to treat estrogen receptor positive breast cancer, reduce the risk of invasive breast cancer following surgery, or reduce the risk of breast cancer in high risk women. |
Drug | Drug Name | Phase | Status | Count |
---|---|---|---|---|
DB00834 | Mifepristone | 0 | Terminated | 1 |
DB01217 | Anastrozole | 1 | Recruiting | 1 |
DB00990 | Exemestane | 1 | Recruiting | 1 |
DB17293 | Hiltonol | 1 | Recruiting | 1 |
DB01006 | Letrozole | 1 | Recruiting | 1 |
DB00608 | Chloroquine | 1 / 2 | Completed | 1 |
DB00169 | Cholecalciferol | 1 / 2 | Withdrawn | 1 |
DB06663 | Pasireotide | 1 / 2 | Terminated | 1 |
DB01217 | Anastrozole | 2 | Recruiting | 1 |
DB00958 | Carboplatin | 2 | Unknown Status | 1 |
DB06374 | Elacestrant | 2 | Recruiting | 1 |
DB00990 | Exemestane | 2 | Recruiting | 1 |
DB14307 | Green tea leaf | 2 | Terminated | 1 |
DB01006 | Letrozole | 2 | Completed | 1 |
DB01006 | Letrozole | 2 | Recruiting | 1 |
DB00704 | Naltrexone | 2 | Terminated | 1 |
DB00107 | Oxytocin | 2 | Terminated | 1 |
DB08877 | Ruxolitinib | 2 | Recruiting | 1 |
DB01266 | Sinecatechins | 2 | Terminated | 1 |
DB00675 | Tamoxifen | 2 | Not Yet Recruiting | 1 |
DB00675 | Tamoxifen | 2 | Recruiting | 2 |
DB00624 | Testosterone | 2 | Recruiting | 1 |
DB00399 | Zoledronic acid | 2 | Completed | 1 |
DB00296 | Ropivacaine | 4 | Completed | 1 |
DB00708 | Sufentanil | 4 | Completed | 1 |
DB01259 | Lapatinib | Not Available | Terminated | 1 |
DB00556 | Perflutren | Not Available | Terminated | 1 |
DB00072 | Trastuzumab | Not Available | Completed | 1 |